A 'springboard' to the future: Genentech, Sanofi and Alnylam execs sound off on pharma's evolving back-to-work plans

As waves of pharma employees headed for the home office last March, countless others stuck around, staffing labs and research facilities to handle work that demands a human touch. That, in fact, is why the world now has drugs and vaccines helping defeat the pandemic.

And now, as drugmakers plot courses back to to the office for thousands of employees, they're looking at ways to expand flexibility for those in-person staffers, too.